After calling for a major discount for Pfizer’s popular transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis, a U.S.

TD Cowen raised the firm’s price target on Alnylam (ALNY) to $371 from $282 and keeps a Buy rating on the shares. The firm updated its ...

Scotiabank started coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research note issued to ...

New data released by Merck suggests AstraZeneca and Sanofi’s Beyfortus, the monoclonal antibody injection that protects ...

Alnylam's Yvonne Greenstreet, at #STATSummit, predicts vutrisiran will become multibillion-dollar product for ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Alnylam Pharmaceuticals (ALNY) been one of those stocks this year? Let's take a ...

Alnylam Pharmaceuticals ALNY announced that it has submitted a Type II Variation to the European Medicines Agency for ...

While Judo Bio was preparing for its public launch, so was another siRNA start-up. City Therapeutics, the latest project of ...

Livforsakringsbolaget Skandia Omsesidigt raised its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free ...

An investigational oral fatty acid synthase (FASN) inhibitor was associated with significant improvements in metabolic ...

The founding CEO of Alnylam Pharmaceuticals Inc. is now leading the charge with newly launched City Therapeutics Inc., which just completed a $135 million series A financing. City’s executive chair, ...

Four IPOs each raised at least $75 million this week as the Fall IPO market continued to hum along, while one company ...